Natera (NASDAQ: NTRA) insider sells 3,000 shares in a planned trade

What happened

Natera, Inc. (NASDAQ: NTRA) insider Solomon Moshkevich sold 3,000 shares on 2026-10-01 under a Rule 10b5-1 trading plan.

The Form 4 lists Moshkevich as PRESIDENT, CLINICALDIAGNOSTICS.

The trades were all in common stock and were split into three sales.

The tranches were 200 shares at $411.62, 954 shares at $413.1066, and 1,846 shares at $415.0691.

Footnotes give transaction ranges of $411.55 to $411.69, $412.8350 to $413.3100, and $414.44 to $415.19 per share.

The filing puts the total value at about $1.24 million, and Moshkevich held 106,914 shares after the sale.

The filing was submitted by one reporting person, and the shares were held directly.

Key numbers

Metric	Latest	Change	Source
Shares sold	3,000 shares		SEC Form 4
Sale value	about $1.24 million		SEC Form 4
Shares held after sale	106,914 shares		SEC Form 4
Sale price range	from $411.62 to $415.07 per share		SEC Form 4
Sale as a share of pre-sale holding	2.7%		Calculated from SEC Form 4

Read more: Natera (NTRA) stock analysis and investment case

Why it matters

OptimistFi's case is that Natera's value depends on proving that clinical adoption and reimbursement can keep scaling while test growth turns into durable cash generation.

This filing is mixed for that view because it shows a planned sale by a senior operator, but it also shows a continuing ownership stake.

The 3,000 shares were about 2.7% of the pre-sale holding, so the trade was a small slice of the position rather than a full reduction.

The filing says the sale was made under a Rule 10b5-1 plan adopted on November 26, 2024.

That timing means the trade schedule was set long before the 2026-10-01 sale, which limits how much investors can read into the transaction.

Because Moshkevich still held 106,914 shares, the report shows ongoing exposure to Natera's stock.

Even so, the report gives a fresh data point on insider activity for investors watching whether rapid test growth is translating into durable cash generation.

Browse: stock research on every company OptimistFi covers

What's next

Natera's next quarterly report is the next scheduled test of the case.

Investors will watch whether the company keeps scaling clinical adoption and reimbursement and whether cash generation improves.

A stronger report would matter more than this planned sale, while weaker results would leave the filing's mixed read in place.

The Form 4 itself does not change the operating story, but the next report will show whether the business keeps moving toward the cash outcome in the investment case.

More from OptimistFi